🇺🇸 FDA

Company profile · Sponsor

Institut

Institut für biomedizinische Analytik NMR-Imaging GmbH

E27A7B8 · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Institut (E27A7B8) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E27A7B8
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. 11C-SB207145, 11C-DASB

    Institut

    Parkinson's disease, Prodromal phase of Parkinson's disease

    phase 3 small molecule active

    1 trial

  2. 18F-AV-1451

    Institut

    Maladie d' Alzheimer, Alzheimer's pathology

    phase 3 small molecule active

    1 trial

  3. 18F-LBT-999

    Institut

    Comatose Traumatic Brain Injury patients

    phase 3 small molecule active

    1 trial

  4. 5-FU medac 50 mg/ml, Injektionslösung, Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, Oxaliplatin medac 5 mg/ml concentrate for solution for infusion

    Institut

    locally advanced resectable adenocarcinoma of the oesophagogastric junction or the stomach

    phase 3 small molecule active

    1 trial

  5. A matching sterile product (Placebo Ophthalmic Solution) will be provided using the same excipient formulation as the active K-321 product., Ripasudil

    Institut

    Fuchs Endothelial Corneal Dystrophy

    phase 3 small molecule active

    1 trial

  6. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    Institut

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  7. Actilyse, polvo y disolvente para solución inyectable y para perfusión, Actilyse, polvo y disolvente para solución inyectable y para perfusión

    Institut

    People with acute ischemic stroke (AIS) due to large vessel occlusion of the anterior circulation.

    phase 3 small molecule active

    1 trial

  8. Afinitor 2.5 mg tablets, Afinitor 10 mg tablets

    Institut

    Children, adolescents and adults with newly diagnosed diffuse intrinsic pontine glioma and other diffuse midline gliomas H3K28M mutant or EZHIP positive

    phase 3 small molecule active

    1 trial

  9. Avastin 25 mg/ml concentrate for solution for infusion., Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.

    Institut

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  10. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion

    Institut

    intermediate-stage hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  11. BAY 94-8862, Finerenone, Placebo coated tablet 002 to BAY 948862 coated tablet

    Institut

    Chronic kidney disease

    phase 3 small molecule active

    1 trial

  12. BENDAFOLIN 10 mg/ml Injektionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, Napabucasin

    Institut

    Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic.

    phase 3 small molecule active

    1 trial

  13. BIOTIN, Medebiotin Fuerte solución inyectable, Medebiotín Fuerte Comprimidos

    Institut

    Metilcrotonilglicinuria, biotinidasa deficit

    phase 3 small molecule active

    1 trial

  14. Budesonida Aldo-Unión 0,5 mg/ml suspensión para inhalación por nebulizador, CUROSURF® 120mg/vial + 240mg/vial Endotracheopulmonary Instillation Suspension

    Institut

    Bronchopulmonary dysplasia, Preterm newborns ≤32 weeks of gestational age.

    phase 3 small molecule active

    1 trial

  15. CELLULOSE, MICROCRYSTALLINE, OSELTAMIVIR , DEXAMETHASONE

    Institut

    Severe Influenza

    phase 3 small molecule active

    1 trial

  16. CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable, Tislelizumab

    Institut

    patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment

    phase 3 small molecule active

    1 trial

  17. COBALAMIN

    Institut

    Hydroxycobalamin deficiency

    phase 3 small molecule active

    1 trial

  18. CONDROSULF 800 mg tabletta

    Institut

    Knee osteoarthritis with moderate to severe pain

    phase 3 small molecule active

    1 trial

  19. CONOXIA, gas medicinal comprimido, Conoxia 100% medicinal gas, cryogenic

    Institut

    ILD

    phase 3 small molecule active

    1 trial

  20. COPINAL 300 mg cápsulas, Placebo has the same composition than imp except the active substance

    Institut

    Chronic liver disease

    phase 3 small molecule active

    1 trial

  21. CYCLOPHOSPHAMIDE, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, THIOTEPA, FLUDARABINE PHOSPHATE, TREOSULFAN, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., BUSULFAN, ETOPOSIDE

    Institut

    Acute Lymphoblastic Leukaemia

    phase 3 small molecule active

    1 trial

  22. CYCLOPHOSPHAMIDE, EPIRUBICIN, TRASTUZUMAB EMTANSINE, PACLITAXEL, DOXORUBICIN, DOCETAXEL, PACLITAXEL ALBUMIN-BOUND, TRASTUZUMAB, CARBOPLATIN, Phesgo 1200 mg/600 mg solution for injection, Phesgo 600 mg/600 mg solution for injection, TRASTUZUMAB, PERTUZUMAB

    Institut

    HER2-positive early breast cancer

    phase 3 small molecule active

    1 trial

  23. Celestone Cronodose suspensión inyectable, Ropivacaína Altan 7,5 mg/ml solución inyectable EFG, PLATELET CONCENTRATE

    Institut

    CHRONIC OMALGIA

    phase 3 small molecule active

    1 trial

  24. Chirhostim

    Institut

    Pancreatic cancer, Intraductal papillary mucinous intraductal neoplasia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Institut?

Institut (E27A7B8) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Institut sponsor?

We track 24 ClinicalTrials.gov-linked programs for Institut, including 11C-SB207145, 11C-DASB and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Institut company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.